LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Impax Laboratories Inc. (“Impax” or the “Company”) (Nasdaq: IPXL) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Impax shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
The investigation revolves around whether Impax and certain of its officers and/or directors violated federal securities laws. On November 3, 2016, Bloomberg News reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Impax, to determine whether they unlawfully colluded with each other to fix generic drug prices.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.